Search

Your search keyword '"Bankir L"' showing total 270 results
Start Over Author "Bankir L"
270 results on '"Bankir L"'

8. Association of a Low-Protein Diet With Slower Progression of CKD

Author

Metzger, M., Yuan, W.L., Haymann, J.P., Flamant, M., Houillier, P., Thervet, E., Boffa, J.J., Vrtovsnik, F., Froissart, M., Bankir, L., Fouque, D., Stengel, B., Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Métabolisme et physiologie rénale (CRC - UMR_S 1138), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Service de néphrologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), The NephroTest CKD cohort study was supported by the following grants: INSERM GIS-IReSP AO 8113LS TGIR (BS), French Ministry of Health AOM 09114 (MFr), INSERM AO 8022LS (BS), Agence de la Biomédecine R0 8156LL (B.S.), AURA (MFr), and Roche 2009-152-447G (MFr)., Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), CHU Tenon [APHP], Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pillet, Lauriane, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre National de la Recherche Scientifique (CNRS)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
glomerular filtration rate, function, end-stage renal disease, vasopressin, [SDV]Life Sciences [q-bio], restriction, urinary urea excretion, dietary protein intake, Urology & Nephrology, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, decline, mortality, rate, [SDV] Life Sciences [q-bio], term-follow-up, nutrition, prevention, Clinical Research, glomerular filtration, mdrd, adherence, chronic kidney-disease, chronic renal-disease
Abstract

Open access article; International audience; Introduction: Reducing protein intake is recommended for slowing chronic kidney disease (CKD) progression, but assessment of its true effectiveness is sparse. Methods: Using the Maroni formula, we assessed dietary protein intake (DPI) from 24-hour urinary urea excretion in 1594 patients (67% men and 33% women) with CKD, 784 of whom also had 7-day food records. Cause-specific hazard ratios (HRs) and 95% confidence intervals for the competing risks of DPI-associated end-stage renal disease (ESRD) or death were estimated in 1412 patients with baseline glomerular filtration rate \textgreater= 15 ml/min per 1.73 m(2), measured by Cr-51-EDTA renal clearance (mGFR). Results: Overall, mean DPI estimated from urea excretion was 1.09 +/- 0.30 g/kg of body weight per day (range = 0.34 - 2.76); 20% of patients had values \textgreater 1.3 g/kg per day, and 1.9% had values \textless 0.6 g/kg per day. Urea excretion and food records produced similar estimates of mean DPI. The lower the mGFR, the lower the mean DPI. Over a median follow-up of 5.6 years, there were 319 ESRD events and 189 pre-ESRD deaths. After adjusting for relevant covariates, each 0.1 g/kg daily higher baseline urea excretion - based DPI or food record - based DPI was associated with an HR for ESRD of 1.05 (95% confidence interval 1.01 - 1.10) or 1.09 (95% confidence interval 1.04 - 1.14), respectively. HRs were stronger in patients with baseline mGFR \textless 30 ml/min per 1.73 m(2). There was no association with mortality. The mean age of the patients was 59 +/- 15 years, and mean body mass index was 26.6 +/- 5.2 kg/m(2). Conclusion: In this prospective observational study, the lower the baseline DPI, the slower the progression toward ESRD. Most importantly, the absence of threshold for the relation between DPI and ESRD risk indicates that there is no optimal DPI in the range observed in this cohort.

Published
2018
Full Text
View/download PDF

12. Supplementary Material for: Validation of Surrogates of Urine Osmolality in Population Studies

Author

Youhanna, S., Bankir, L., Jungers, P., Porteous, D., Polasek, O., Bochud, M., Hayward, C., and Devuyst, O.

Subjects
fungi
Abstract

Background: The importance of vasopressin and/or urine concentration in various kidney, cardiovascular, and metabolic diseases has been emphasized recently. Due to technical constraints, urine osmolality (Uosm), a direct reflect of urinary concentrating activity, is rarely measured in epidemiologic studies. Methods: We analyzed 2 possible surrogates of Uosm in 4 large population-based cohorts (total n = 4,247) and in patients with chronic kidney disease (CKD, n = 146). An estimated Uosm (eUosm) based on the concentrations of sodium, potassium, and urea, and a urine concentrating index (UCI) based on the ratio of creatinine concentrations in urine and plasma were compared to the measured Uosm (mUosm). Results: eUosm is an excellent surrogate of mUosm, with a highly significant linear relationship and values within 5% of mUosm (r = 0.99 or 0.98 in each population cohort). Bland-Altman plots show a good agreement between eUosm and mUosm with mean differences between the 2 variables within ±24 mmol/L. This was verified in men and women, in day and night urine samples, and in CKD patients. The relationship of UCI with mUosm is also significant but is not linear and exhibits more dispersed values. Moreover, the latter index is no longer representative of mUosm in patients with CKD as it declines much more quickly with declining glomerular filtration rate than mUosm. Conclusion: The eUosm is a valid marker of urine concentration in population-based and CKD cohorts. The UCI can provide an estimate of urine concentration when no other measurement is available, but should be used only in subjects with normal renal function.

Published
2017
Full Text
View/download PDF

20. Acid-base / Electrolytes

Author

An, J. N., primary, Lee, J. P., additional, Oh, Y. K., additional, Lim, C. S., additional, Shoaf, S., additional, Bricmont, P., additional, Mallikaarjun, S., additional, Volpini, R. A., additional, De Braganca, A. C., additional, Canale, D., additional, Goncalves, J. G., additional, Brandao, T. P. B., additional, Andrade, L., additional, Seguro, A. C., additional, Shimizu, M. H. M., additional, Lee, J., additional, Joo, K. W., additional, Jung, Y. C., additional, Earm, J.-H., additional, Han, J. S., additional, Poch, E., additional, Burst, V., additional, Greenberg, A., additional, Makin, A., additional, Chase, S., additional, Walther, B., additional, Blom, R. E., additional, Van Dijken, G. D., additional, Hene, R. J., additional, Yu-Bao, W., additional, Valerie, L., additional, Thomas, E., additional, Arvid, M., additional, Alain, D., additional, Pierre-Yves, M., additional, Feraille, E., additional, Tovbin, D., additional, Avnon, L., additional, Bloch, D., additional, Zlotnik, M., additional, Abdelkadir, A., additional, Storch, S., additional, Fezeu, L., additional, Bankir, L., additional, Hansel, B., additional, Guerrot, D., additional, Anzai, N., additional, Jutabha, P., additional, Tolle, M., additional, Jankowski, V., additional, Kretschmer, A., additional, Santos, R. A. S., additional, Zidek, W., additional, Jankowski, J., additional, Bader, M., additional, Bourderioux, M., additional, Ida Chiara, G., additional, Thao, N.-K., additional, Ludovic, J., additional, Cerina, C., additional, Gabrielle, P., additional, Bertrand, K., additional, Estelle, E., additional, Bernard, E., additional, Aleksander, E., additional, Picard, N., additional, and Loffing, J., additional

Published
2012
Full Text
View/download PDF

21. Hormones

Author

Simoes-Silva, L., primary, Moreira-Rodrigues, M., additional, Quelhas-Santos, J., additional, Fernandes-Cerqueira, C., additional, Pestana, M., additional, Soares-Silva, I., additional, Sampaio-Maia, B., additional, Bankir, L., additional, Leopold, F., additional, Nadine, B., additional, Roussel, R., additional, Balkau, B., additional, Michel, M., additional, Daniel, B., additional, Kurnatowska, I., additional, Grzelak, P., additional, Kaczmarska, M., additional, Masajtis-Zagajewska, A., additional, Stefanczyk, L., additional, Nowicki, M., additional, Niemczyk, S., additional, Niemczyk, L., additional, Szamotulska, K., additional, Bartoszewicz, Z., additional, Dubchak, I., additional, Syta, U., additional, Matuszkiewicz-Rowinska, J., additional, Dudek, M., additional, Brodowska, D., additional, Wozniacki, L., additional, Gomolka, M., additional, Rymarz, A., additional, Lacquaniti, A., additional, Donato, V., additional, Fazio, M. R., additional, Lucisano, S., additional, Cernaro, V., additional, Lupica, R., additional, and Buemi, M., additional

Published
2012
Full Text
View/download PDF

29. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Author

Serradeil-Le Gal, C, primary, Lacour, C, additional, Valette, G, additional, Garcia, G, additional, Foulon, L, additional, Galindo, G, additional, Bankir, L, additional, Pouzet, B, additional, Guillon, G, additional, Barberis, C, additional, Chicot, D, additional, Jard, S, additional, Vilain, P, additional, Garcia, C, additional, Marty, E, additional, Raufaste, D, additional, Brossard, G, additional, Nisato, D, additional, Maffrand, J P, additional, and Le Fur, G, additional

Published
1996
Full Text
View/download PDF

39. Low water intake and risk for new-onset hyperglycemia.

Author

Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L, D.E.S.I.R. Study Group, Roussel, Ronan, Fezeu, Léopold, Bouby, Nadine, Balkau, Beverley, Lantieri, Olivier, Alhenc-Gelas, François, Marre, Michel, and Bankir, Lise

Abstract

Objective: Water intake alters vasopressin secretion. Recent findings reveal an independent association between plasma copeptin, a surrogate for vasopressin, and risk of diabetes.Research Design and Methods: Participants were 3,615 middle-aged men and women, with normal baseline fasting glycemia (FG), who were recruited in a 9-year follow-up study. Odds ratios (ORs) and 95% CIs for the incidence of hyperglycemia (FG ≥6.1 mmol/L or treatment for diabetes) were calculated according to daily water intake classes based on a self-administered questionnaire.Results: During follow-up, there were 565 incident cases of hyperglycemia. After adjustment for confounding factors, ORs (95% CIs) for hyperglycemia associated with classes of water intake (<0.5 L, n = 677; 0.5 to <1.0 L, n = 1,754; and >1.0 L, n = 1,184) were 1.00, 0.68 (0.52-0.89), and 0.79 (0.59-1.05), respectively (P = 0.016).Conclusions: Self-reported water intake was inversely and independently associated with the risk of developing hyperglycemia. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

45. Renal function and concentrating ability in a desert rodent: The gundi (Ctenodactylus vali).

Author

Rouffignac, C., Bankir, L., Roinel, N., Philippe, P., Soyeux, N., and Malorey, P.

Abstract

Clearance and cortical micropuncture experiments were carried out on non diuretic gundis. In this species, the kidney has a long and well developed papilla but, unlike other desert rodents, the vascular organization of the outer medulla is very simple. After withdrawal of water supply for either 24 h or 3 days before the experiments, the urine osmolality was only 1,361±57, n=9, before and 1,136±89 mosmol ·kg during anesthesia. The GFR per 100 g B. W. (0.450 ml ·min) is lower than in the rat studied under similar conditions. With regard to electrolytes the tubular handling of Na, Ca, K and Mg is similar to that observed for another desert rodent, psammomys obesus. For P, massive reabsorption (more than 30% of the filtered load) takes place along the distal convoluted tubule. The relatively poor concentrating ability of the gundi's kidney is not due to a lack of medullary recycling of urea since a net addition of urea to short loops of Henle is observed in this species. Physiological and morphological observations concerning the gundi and other desert rodent species suggest that the vascular bundle development in the outer medulla might affect the renal response to water deprivation. [ABSTRACT FROM AUTHOR]

Published
1981
Full Text
View/download PDF

47. Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidus.

Author

Pouzet, B, Serradeil-Le Gal, C, Bouby, N, Maffrand, J P, Le Fur, G, and Bankir, L

Abstract

In a previous study we observed that acute administration of the selective antagonist of vasopressin (AVP) V2 receptors, SR 121463A (SR), aggravated the symptoms of diabetes insipidus (DI) in homozygous Brattleboro rats (an AVP-deficient strain). The present study investigates in more details the acute and chronic effects of SR in DI rats.

Published
2001
Full Text
View/download PDF

49. Renal function and concentrating ability in a desert rodent: The gundi(Ctenodactylus vali)

Author

Rouffignac, C., Bankir, L., Roinel, N., Philippe, P., Soyeux, N., and Malorey, P.

Abstract

Clearance and cortical micropuncture experiments were carried out on non diuretic gundis. In this species, the kidney has a long and well developed papilla but, unlike other desert rodents, the vascular organization of the outer medulla is very simple. After withdrawal of water supply for either 24 h or 3 days before the experiments, the urine osmolality was only 1,361±57,n=9, before and 1,136±89 mosmol ·kg-1 during anesthesia. The GFR per 100 g B. W. (0.450 ml ·min-1) is lower than in the rat studied under similar conditions. With regard to electrolytes the tubular handling of Na, Ca, K and Mg is similar to that observed for another desert rodent, psammomys obesus. For P, massive reabsorption (more than 30% of the filtered load) takes place along the distal convoluted tubule. The relatively poor concentrating ability of the gundi's kidney is not due to a lack of medullary recycling of urea since a net addition of urea to short loops of Henle is observed in this species. Physiological and morphological observations concerning the gundi and other desert rodent species suggest that the vascular bundle development in the outer medulla might affect the renal response to water deprivation.

Published
1981
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results